Thanks for joining us – if you would like to re-watch the webinar, the video has been made available below to watch again. Over the past two decades, the biopharma community has faced significant challenges in advancing exciting and potentially…
Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate to the Moubray Building at Edinburgh Technopole, part of Pioneer Group. Following a detailed strategic review, the company has embarked on…
Biomanufacturing uses biological systems to produce commercially relevant molecules– such as peptides, proteins, antibodies and small molecules – at scale. Choosing the ideal host organism is crucial for an efficient and economical bioprocess, and mammalian cell lines and Escherichia coli are currently the…
Many COVID-19 vaccines work by presenting fragments of the SARS-CoV-2 spike protein – the receptor-binding domain (RBD) – to the body to generate an immune response. However, newly arising SARS-CoV-2 variants are increasingly able to evade this response due to…
Enzyme evolution can be used to take a wild-type enzyme that is in some way unsuitable for a bioprocess of interest and create a strain with enhanced capabilities. This iterative process is based on the design-build-test-learn (DBTL) cycle,1 and can be used…
Cell line development is a critical aspect of biotechnology and pharmaceutical research, and plays an important role in Ingenza’s CRDMO services. The process involves establishing and maintaining genetically identical mammalian cells in culture for use in a variety of processes, such…
Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with Cellugy to accelerate the development of its innovative platform for producing biofabricated cellulose. This technology will provide a sustainable alternative to fossil-based petrochemicals in various industrial applications, starting with personal care…
The performance and economics of any bioprocess are significantly impacted by the choice of host platform. Ingenza’s diverse range of bacterial, yeast and mammalian production platforms is an excellent foundation for biomanufacturing development. In this white paper, Rita Cruz, Section Head of…
Ingenza has a comprehensive suite of validated analytical methods and assays that can be readily employed to fully characterise both small molecules and biologics targets throughout all stages of bioprocess development and optimisation. We aim to deliver high quality results…
Thanks for joining us – if you would like to re-watch the webinar, the video has been made available below to watch again. Discover how Ingenza masters the production of complex proteins with viable, scalable and cost-effective bioprocesses. In this…